Results 91 to 100 of about 70,680 (286)

From Business model to Business model portfolio in the european biopharmaceutical industry [PDF]

At the crossroad of firm's core competencies and of the anticipations of consumers' needs, the business model approach complements corporate and business strategy approaches.
Tristan Rouselle, Valérie Sabatier, Vincent Mangematin   +2 more
core  

Biopharmaceutical benchmarks 2018 [PDF]

Nature Biotechnology, 2018
Monoclonal antibodies (mAbs) continue to reign supreme, although cellular and gene therapies are slowly starting to gather momentum. Burgeoning growth in biosimilars may threaten future brand monopolies for mAbs and other biologics.
openaire   +2 more sources

Efficacy and Safety of Subcutaneous Anifrolumab in Systemic Lupus Erythematosus: A Randomized, Phase 3 Study

Arthritis &Rheumatology, EarlyView.
Objective The multinational, phase 3, double‐blind, placebo‐controlled TULIP‐SC trial evaluated the efficacy and safety of subcutaneous anifrolumab in adults who have moderate to severe systemic lupus erythematosus (SLE) activity, despite receiving standard therapy. Methods Adults with SLE received subcutaneous anifrolumab 120 mg or placebo once weekly
Susan Manzi, Ian N. Bruce, Eric F. Morand, Richard Furie, Yoshiya Tanaka, Kenneth C. Kalunian, Anca Askanase, Patricia Puzio, Emon Khan, Jenny Wissmar, Michael Song, Catharina Lindholm, for the TULIP‐SC investigators   +12 more
wiley   +1 more source

High-Quality Development of China's Biopharmaceutical Industry: Current Status, Challenges, and Strategic Measures [PDF]

中国工程科学
The biopharmaceutical industry, serving as the core driving force in the realm of modern medicine, assumes an irreplaceable role in safeguarding national health, propelling economic development, and fostering technological advancements.
Lai Xu, Heshui Yu, Zhaopin Wang, Ying Li, Jingjing Yang, Xiangmei Chen, Xiaosong Gu   +6 more
doaj   +1 more source

Anifrolumab Treatment Leads to Rapid Reduction in Urinary Biomarkers of Intrarenal Inflammation in Lupus Nephritis: Results From the Phase 2 Randomized Trial

Arthritis &Rheumatology, EarlyView.
Objective Lupus nephritis (LN) is one of the most severe manifestations of systemic lupus erythematosus (SLE) and is partially driven by type I interferon signaling. Anifrolumab, an approved treatment for patients with SLE, has been investigated in a phase 2 trial in patients with LN receiving standard therapy (TULIP‐LN, ClinicalTrials.gov identifier ...
Andrea Fava, Michelle Petri, Patrick G. Gavin, Eszter Csomor, Philip Z. Brohawn, Daniel Muthas, Adam Platt, Catharina Lindholm, Nicola Ferrari   +8 more
wiley   +1 more source

Do Firms Benefit from Being Present in Multiple Technology Clusters? An Assessment of the Technological Performance of Biopharmaceutical Firms [PDF]

Firms active in knowledge-intensive fields are increasingly organizing their R&D activities on an international scale. This paper investigates whether firms active in biotechnology can improve their technological performance by developing R&D activities ...
Bart Leten, Bart Van Looy, Catherine Lecocq, Jeroen Kusters   +3 more
core  

Multi‐omic profiling reveals immune cell priming signature linked to lupus prognosis

Arthritis &Rheumatology, Accepted Article.
Objective Systemic lupus erythematosus (SLE) is a multi‐organ disease with widespread immune dysregulation and significant unmet clinical need. Blood‐based gene expression studies have advanced our understanding of SLE pathogenesis but may overlook critical tissue‐specific mechanisms that drive disease heterogeneity and progression.
Michael A. Smith, Dominic Sinibaldi, Saifur Rahman, Chia‐Chien Chiang, Anna M. Hansen, Jill Henault, Carlos P. Roca, Shu Wang, Kamelia Zerrouki, Rebecca Filippi, Christopher Groves, Zerai Manna, Jun Chu, Michael Davis, Sarthak Gupta, Christopher Morehouse, Melissa de los Reyes, Rachel Ettinger, Roland Kolbeck, Mariana J. Kaplan, Miguel A. Sanjuan, Richard M. Siegel, Sarfaraz A. Hasni, Kerry A. Casey   +23 more
wiley   +1 more source

Transient Transfection of Rolling‐Circle Amplified DNA in Biomanufacturing‐Relevant Mammalian Cell Lines: A Comparison of Transfection Conditions for Optimal Protein Expression

Biotechnology and Applied Biochemistry, EarlyView.
ABSTRACT Rolling‐circle amplification (RCA) is a completely synthetic and rapid mechanism for scaling‐up bulk DNA that eliminates requirements for large‐scale bacterial fermentation. Several reports have described the surprising ability of large unprocessed (hyperbranched) rolling circle‐amplified DNA (RCA DNA) to effectively transfect cultured cells ...
Evelina Loghin, Erik Kvam, Lisa Lowery, Nathan Hudson, Jenny Keen, Brian Davis, Roger B. Dodd, Christine Surrette, John Nelson   +8 more
wiley   +1 more source

Technological Knowledge Base, R&D Organization Structure and Alliance Formation: Evidence from the Biopharmaceutical Industry [PDF]

We explore how an incumbent firm's internal knowledge and organization structure influences its strategic alliance formation. We propose that the firm's knowledge breadth and the centrality of its R&D organization structure positively influence its ...
Charles Baden-Fuller, Jing Zhang, Vincent Mangematin   +2 more
core  

From cramming to binge‐watching: Integrating documentary‐based assessment into a pharmacology and toxicology curriculum—a qualitative study

British Journal of Clinical Pharmacology, EarlyView.
Abstract Aims In the context of pharmacology and toxicology education, there is a growing shift toward programmatic assessment models that prioritize longitudinal learning, reflection and development of higher‐order cognitive skills. As part of this transition, we are exploring alternative and more meaningful forms of assessment. This qualitative study
Narin Akrawi, Heleen van der Sijs, Floor van Rosse   +2 more
wiley   +1 more source